Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christian Ramers

Internal Medicine San Diego, CA Medical Doctor

NPI 1730381385 CMS profile 260569

4094 4Th Ave, San Diego, CA 92103

Open in the dashboard

General payments

$675,194

898 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christian Ramers of San Diego, CA is reported in the CMS Open Payments database as having received $675,194 across 898 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $203 2
2024 General $110,174 117
2023 General $99,426 123
2022 General $127,815 168
2021 General $59,120 95
2020 General $79,283 75
2019 General $199,173 318

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christian Ramers
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christian Ramers were reported at $203. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christian Ramers Internal Medicine median Middle half National median
2019 $199,173 $159 $48–$570 $163
2020 $79,283 $119 $33–$402 $114
2021 $59,120 $135 $37–$521 $132
2022 $127,815 $141 $42–$496 $149
2023 $99,426 $149 $45–$519 $160
2024 $110,174 $154 $47–$537 $164
2025 $203 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $446,536 531 payments
  2. ViiV Healthcare Company $101,684 106 payments
  3. AbbVie, Inc. $100,277 153 payments
  4. Beckman Coulter, Inc. $11,000 1 payment
  5. Merck Sharp & Dohme Corporation $8,315 12 payments
  6. Pfizer Inc. $3,223 4 payments
  7. Theratechnologies Inc. $1,520 2 payments
  8. GlaxoSmithKline, LLC. $1,059 9 payments
  9. Janssen Products, LP $860 1 payment
  10. Janssen Biotech, Inc. $602 76 payments
  11. Other $118 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $411,062 187 payments
  2. Consulting Fee $167,490 62 payments
  3. Travel and Lodging $74,269 228 payments
  4. Food and Beverage $19,714 417 payments
  5. Honoraria $2,610 2 payments
  6. Education $48 2 payments
Products named General payments · program years 2019–2025
  1. Epclusa $240,279 241 payments
  2. MAVYRET $90,741 140 payments
  3. DOVATO $66,059 56 payments
  4. Veklury $39,662 46 payments
  5. APRETUDE $21,895 25 payments
  6. Biktarvy $18,803 11 payments
  7. Descovy $15,041 18 payments
  8. Truvada $14,319 12 payments
  9. Vemlidy $10,005 4 payments
  10. DELSTRIGO $5,554 8 payments
  11. Other $8,907 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

1,366

Median for Internal Medicine: 777

Drug cost

$996,276

Median for Internal Medicine: $73,373

Branded share of claims

36.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 127 $495,656
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 23 $83,968
Dovato Dolutegravir Sodium/Lamivudine Brand 28 $78,717
Juluca Dolutegravir/Rilpivirine Brand 23 $76,881
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 20 $69,024
Prezcobix Darunavir/Cobicistat Brand 28 $65,204
Vemlidy Tenofovir Alafenamide Brand 39 $53,532
Pifeltro Doravirine Brand 18 $29,437
Ozempic Semaglutide Brand 13 $17,005
Linzess Linaclotide Brand 12 $6,168

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epclusa
$38,516 — —
MAVYRET
$13,574 — —
Veklury
$6,959 — —
DOVATO
$3,932 28 —
Vemlidy
$2,070 39 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

898 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record